Novo Nordisk Sets 2030 Goal of Five-Plus Blockbuster Launches, Details Obesity Pipeline Rollout

Novo Nordisk查看公司主页 outlined a multi-year plan to rebuild growth at its Capital Markets Day in London on Monday, targeting more than five new blockbuster launches by 2030 and more than 150 billion Danish kroner ($23 billion) in sales from pipeline drugs by 2035. The company's 2025 total sales were 309.06 billion kroner.

Chief Executive Mike Doustdar said the company will continue to strengthen its diabetes (搜索)搜索该疾病 portfolio and expand its obesity (搜索)搜索该疾病 pipeline while diversifying into new areas. Novo Nordisk查看公司主页 will build out future growth in blood and endocrine disorders, liver diseases and cardiovascular diseases, he said.

Obesity injectables mapped through the decade

Management detailed a staged rollout for its next-generation obesity (搜索)搜索该疾病 injectables. The company is targeting a launch of its CagriSema查看药品详情 combination early next year, followed by standalone cagrilintide查看药品详情 and high-dose CagriSema in 2028, before advancing zenagamtide (搜索)搜索该药品.

Doustdar said Novo aims to reach more than 60 million patients globally by 2030 and to scale up manufacturing tenfold to supply 15 million patients with oral obesity (搜索)搜索该疾病 therapies by the end of the decade. The company is also accelerating expansion of its pill portfolio and aims to have at least five oral assets in clinical trials before the end of this year.

Oral Wegovy uptake and the semaglutide patent cliff

Doustdar said the oral Wegovy查看药品详情 pill has achieved a record 7 million prescriptions in the U.S. to date, with 90% of those sales flowing through direct cash-pay channels. The recently launched weight-loss pills have given Novo Nordisk查看公司主页 an early lead in the new oral market, and Doustdar has previously said the early signs give him hope the pills could help regain some of the company's lost market share.

The company has ceded its lead in the weight-loss injection market to U.S. rival Eli Lilly查看公司主页. At the same time, semaglutide查看药品详情, the active ingredient in Ozempic查看药品详情 and Wegovy查看药品详情, has started to lose exclusivity in a number of markets, opening the door to cheaper generic versions. The semaglutide patent has lost exclusivity in Canada, India, Brazil and Turkey so far this year, while in Europe and the U.S. the exclusivity period runs into the early 2030s. Doustdar said the company will "fiercely compete" for semaglutide volumes in both the markets that still retain exclusivity and those that have already lost it.

Novo Nordisk查看公司主页 has previously cautioned that it expects the launch of generic drugs to hit sales this year, and that lower pricing in the key U.S. market following a deal struck with the Trump administration to cut the cost of obesity (搜索)搜索该疾病 drugs will also dent results. Its most recent group guidance points to an adjusted sales fall of up to 6% at constant exchange rates this year.

Recent clinical setbacks

Elsewhere in the portfolio, the company has faced setbacks. Trial results from an experimental cardiovascular drug did not show the expected risk reduction for heart attack or stroke, while its next-generation obesity (搜索)搜索该疾病 and diabetes (搜索)搜索该疾病 drug CagriSema查看药品详情 disappointed in terms of its blood sugar-lowering effect compared with Eli Lilly查看公司主页's tirzepatide查看药品详情, according to analysts.

Restructuring and pipeline strategy

Doustdar took charge of the company last year and has overseen an initial flurry of acquisitions and a boardroom shakeup. Total departures linked to its corporate restructuring have reached 13,000 employees, following an initial round of 9,000 cuts and an additional 4,000 subsequent exits.

Doustdar told The Wall Street Journal last month that he would continue looking for potential assets and technologies to buy that could complement the company's current pipeline and therapeutic areas, while ruling out large transformative deals. The company last week rebranded as Novo, betting that a shorter name will help it resonate more with consumers as it competes with Eli Lilly查看公司主页, while keeping Novo Nordisk查看公司主页 as its legal name globally.